

Provided by:



**Advanced Practice Education Committee
- Presentation Series 2025-2026**

**Advanced Practice Education Committee - Presentation Series 2025-2026 - 6/17/2026 Pharmacologic
Management of Obstructive Hypertrophic Cardiomyopathy
June 17, 2026
1:30 PM - 2:30 PM**

Target Audience

This program has been designed for ALL SPECIALTIES

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Review a wide range of topics to deepen the knowledge base of Penn Medicine Advanced Practice Providers
- 2 Discuss current medical standards from an interprofessional perspective
- 3 Discuss standard of care practices to the clinical or disease scenario using an interdisciplinary perspective

Session Educational Objectives

After completing this educational activity, participants should be able to:

- 1 Discuss the advantages and disadvantages associated with the use of guideline-directed medical therapy in patients with obstructive hypertrophic cardiomyopathy
- 1 Discuss benefits and monitoring parameters required for an individual who qualifies for cardiac myosin inhibitors
- 2 Describe how a patient case is to select appropriate therapeutic strategies for obstructive hypertrophic cardiomyopathy

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit:

Physicians: This activity is not approved for *AMA PRA Category 1 Credit™*.

Nurses: This activity is for **1.00** contact hours.

Pharmacists: This activity is not approved for pharmacy contact hours.

PAs: Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for **1.00** AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

Acknowledgement of Commercial Support*: None

For more information, please contact
Benjamin Gitter, Katherine Gelinne, Kelsey Sumple, Radha Parekh
(215) 760-9665, (267) 593-0505, (860) 335-8101, (267) 640-8736
Benjamin.gitter@penntmedicine.upenn.edu, Katherine.Gelinne@penntmedicine.upenn.edu,
kelsey.sumple@penntmedicine.upenn.edu, radha.parekh@penntmedicine.upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships(RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Linsey S Chacko, CRNP	Nurse Planner	Nothing to disclose - 02/13/2026
Tiffany Gardner, PharmD	Faculty	Nothing to disclose - 06/04/2026
Katherine Gelinne, PA-C	Physician Assistant Planner	Nothing to disclose - 06/01/2026
Benjamin Gitter, PA-C	Course Director	Nothing to disclose - 11/11/2025
Lisa Marshall, PA-C	Course Director, Nurse Planner	Nothing to disclose - 02/13/2026
Kelsey Sumple, PA-C	Physician Assistant Planner	Nothing to disclose - 08/25/2025

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected